[A17-29] Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 04.01.2018
Commission awarded on 03.07.2017 by the Federal Joint Committee (G-BA).
Locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.